ABBVIE INC (4AB.DE) Stock Price, Quote, News and Overview
FRA:4AB - Deutsche Boerse Ag - US00287Y1091 - Common Stock - Currency: EUR
4AB.DE Quote, Performance and Key Statistics
ABBVIE INC
FRA:4AB (2/4/2025, 7:00:00 PM)
182.96
-0.24 (-0.13%)
The current stock price of 4AB.DE is 182.96 EUR. In the past month the price increased by 5.7%. In the past year, price increased by 13.29%.
4AB.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| AMG.DE | AMGEN INC | 14.96 | 149.57B | ||
| 1AMGN.MI | AMGEN INC | 14.81 | 148.09B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 937.76 | 118.34B | ||
| GIS.DE | GILEAD SCIENCES INC | 21.97 | 117.44B | ||
| ARGX.BR | ARGENX SE | N/A | 37.64B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 27.07B | ||
| IDP.DE | BIOGEN INC | 8.75 | 20.15B | ||
| 0QF.DE | MODERNA INC | N/A | 13.30B | ||
| 1MRNA.MI | MODERNA INC | N/A | 13.08B | ||
| ALEMS.BR | EUROPEAN MEDICAL SOLUTIONS S | N/A | 9.95B | ||
| GLPG.AS | GALAPAGOS NV | 6.99 | 1.44B | ||
| NVV1.DE | NOVAVAX INC | N/A | 1.30B |
Related stock screener links
About 4AB.DE
Company Profile
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 50,000 full-time employees. The company went IPO on 2013-01-02. The company offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Diffuse large B-cell lymphoma, and others. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders, and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers, and others. The company offers NX-13 for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). The company also offers CEL383 for the treatment of inflammatory bowel disease.
Company Info
ABBVIE INC
1 N Waukegan Rd
North Chicago ILLINOIS US
Employees: 50000
Company Website: https://www.abbvie.com/
Investor Relations: https://investors.abbvie.com
Phone: 18479327900
4AB.DE FAQ
What is the stock price of 4AB.DE?
The current stock price of 4AB.DE is 182.96 EUR.
What is the symbol for ABBVIE INC stock?
The exchange symbol of ABBVIE INC is 4AB and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is 4AB.DE stock listed?
4AB.DE stock is listed on the Deutsche Boerse Ag exchange.
Is 4AB.DE a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for 4AB.DE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of 4AB.DE.
Does 4AB.DE stock pay dividends?
4AB.DE has a dividend yield of 3.73%. The yearly dividend amount is currently 5.96.
What is the Price/Earnings (PE) ratio of 4AB.DE?
The PE ratio for 4AB.DE is 18.69. This is based on the reported non-GAAP earnings per share of 9.79 and the current share price of 182.96 EUR.
4AB.DE Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to 4AB.DE. When comparing the yearly performance of all stocks, 4AB.DE turns out to be only a medium performer in the overall market: it outperformed 46.46% of all stocks.
4AB.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE. While 4AB.DE belongs to the best of the industry regarding profitability, there are concerns on its financial health.
4AB.DE Financial Highlights
Over the last trailing twelve months 4AB.DE reported a non-GAAP Earnings per Share(EPS) of 9.79. The EPS increased by -8.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 9.15% | ||
| ROA | 3.54% | ||
| ROE | 84.23% | ||
| Debt/Equity | 9.7 |
4AB.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 79% to 4AB.DE. The Buy consensus is the average rating of analysts ratings from 36 analysts.
For the next year, analysts expect an EPS growth of 22.65% and a revenue growth 5.63% for 4AB.DE